Literature DB >> 9563662

Tumours of the minor salivary glands.

A S Jones1, N J Beasley, D J Houghton, T R Helliwell, D J Husband.   

Abstract

One hundred and forty-five patients were identified with minor salivary gland tumours. General information and tumour-specific information on stage, grade of tumour, resection margins, recurrence and survival were collected. Data was analysed by both univariate and multivariate methods. Indices predicting tumour recurrence and survival were analysed. Forty-two benign lesions, mostly pleomorphic adenomas were identified, one recurred, all survived. One hundred and three malignant lesions were identified, mostly adenoid cystic carcinomas (70%) or mucoepidermoid carcinomas (19%). Late stage disease and the presence of neck node metastases predicted both early recurrence and high eventual mortality. Survival was favoured by the histological type (mucoepidermoid > adenoid cystic), site of primary (oral cavity and oropharynx > nose, sinuses and larynx) and good general condition. Many tumours recurred after 5 years of disease-free survival and late mortality was a feature (80% survival at 5 years, 20% at 20 years). Many patients survive some time with either local recurrence or distant metastases. Long-term follow-up is advocated as local or distant recurrence may be treatable. The value of super radical treatment of the primary is questionable given the likelihood of recurrence at distant sites.

Entities:  

Mesh:

Year:  1998        PMID: 9563662     DOI: 10.1046/j.1365-2273.1998.00088.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  8 in total

1.  Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Authors:  Claudia Scherl; Marlen Haderlein; Abbas Agaimy; Konstantinos Mantsopoulos; Michael Koch; Maximilian Traxdorf; Rainer Fietkau; Philipp Grundtner; Heinrich Iro
Journal:  Strahlenther Onkol       Date:  2019-07-26       Impact factor: 3.621

2.  The prognostic significance of β-catenin, cyclin D1 and PIN1 in minor salivary gland carcinoma: β-catenin predicts overall survival.

Authors:  Sven Schneider; Dietmar Thurnher; Rudolf Seemann; Markus Brunner; Lorenz Kadletz; Bahil Ghanim; Klaus Aumayr; Gregor Heiduschka; Claudia Lill
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-24       Impact factor: 2.503

3.  Intraoral minor salivary gland tumours: a retrospective study from a dental and maxillofacial surgery centre in salem, Tamil Nadu.

Authors:  Maya Ramesh; Ramesh Krishnan; George Paul
Journal:  J Maxillofac Oral Surg       Date:  2013-03-09

Review 4.  Imaging of lumps and bumps in the nose: a review of sinonasal tumours.

Authors:  Sudip Das; Claudia F E Kirsch
Journal:  Cancer Imaging       Date:  2005-12-09       Impact factor: 3.909

Review 5.  Polymorphous low-grade adenocarcinoma: an analysis of epidemiological studies and hints for pathologists.

Authors:  Vera Cavalcanti de Araujo; Fabricio Passador-Santos; Cecilia Turssi; Andresa Borges Soares; Ney Soares de Araujo
Journal:  Diagn Pathol       Date:  2013-01-15       Impact factor: 2.644

6.  Mucoepidermoid carcinoma of the tonsil: a very rare presentation.

Authors:  S J Jarvis; V Giangrande; P A Brennan
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-08       Impact factor: 2.124

7.  ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma.

Authors:  Ulana Kotowski; Lorenz Kadletz; Sven Schneider; Felicitas Oberndorfer; Boban M Erovic; Matthaeus Ch Grasl; Claudia Lill; Gregor Heiduschka
Journal:  Pathol Oncol Res       Date:  2018-10-29       Impact factor: 3.201

8.  Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center.

Authors:  Nikolina Kesar; Panagiotis Balermpas; Jens von der Grün; Ria Winkelmann; Franz Rödel; Sven Balster; Thomas Neumayer; Shahram Ghanaati; Christian Brandts; Iris Burck; Daniel Martin; Claus Rödel
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-03-24       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.